» Articles » PMID: 25035206

Risk Prediction Models of Locoregional Failure After Radical Cystectomy for Urothelial Carcinoma: External Validation in a Cohort of Korean Patients

Overview
Specialties Oncology
Radiology
Date 2014 Jul 19
PMID 25035206
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the predictive accuracy and general applicability of the locoregional failure model in a different cohort of patients treated with radical cystectomy.

Methods And Materials: A total of 398 patients were included in the analysis. Death and isolated distant metastasis were considered competing events, and patients without any events were censored at the time of last follow-up. The model included the 3 variables pT classification, the number of lymph nodes identified, and margin status, as follows: low risk (≤pT2), intermediate risk (≥pT3 with ≥10 nodes removed and negative margins), and high risk (≥pT3 with <10 nodes removed or positive margins).

Results: The bootstrap-corrected concordance index of the model 5 years after radical cystectomy was 66.2%. When the risk stratification was applied to the validation cohort, the 5-year locoregional failure estimates were 8.3%, 21.2%, and 46.3% for the low-risk, intermediate-risk, and high-risk groups, respectively. The risk of locoregional failure differed significantly between the low-risk and intermediate-risk groups (subhazard ratio [SHR], 2.63; 95% confidence interval [CI], 1.35-5.11; P<.001) and between the low-risk and high-risk groups (SHR, 4.28; 95% CI, 2.17-8.45; P<.001). Although decision curves were appropriately affected by the incidence of the competing risk, decisions about the value of the models are not likely to be affected because the model remains of value over a wide range of threshold probabilities.

Conclusions: The model is not completely accurate, but it demonstrates a modest level of discrimination, adequate calibration, and meaningful net benefit gain for prediction of locoregional failure after radical cystectomy.

Citing Articles

Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy.

Ernandez J, Kaul S, Fleishman A, Korets R, Chang P, Wagner A Bladder Cancer. 2024; 8(4):405-417.

PMID: 38994178 PMC: 11181795. DOI: 10.3233/BLC-220031.


Perioperative therapy in muscle invasive bladder cancer.

Chatterjee A, Bakshi G, Pal M, Kapoor A, Joshi A, Prakash G Indian J Urol. 2021; 37(3):226-233.

PMID: 34465951 PMC: 8388335. DOI: 10.4103/iju.IJU_540_20.


Patterns of Locoregional Recurrence after Radical Cystectomy for Stage T3-4 Bladder Cancer: A Radiation Oncologist's Point of View.

Kim H, Chun J, Kim T, Yang G, Shin S, Kim J Yonsei Med J. 2021; 62(7):569-576.

PMID: 34164953 PMC: 8236349. DOI: 10.3349/ymj.2021.62.7.569.


Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer.

Fischer-Valuck B, Michalski J, Mitra N, Christodouleas J, DeWees T, Kim E Cancer Med. 2019; 8(8):3698-3709.

PMID: 31119885 PMC: 6639450. DOI: 10.1002/cam4.2102.


Trimodality therapy for bladder cancer: modern management and future directions.

Pham A, Ballas L Curr Opin Urol. 2019; 29(3):210-215.

PMID: 30855374 PMC: 7440298. DOI: 10.1097/MOU.0000000000000601.